|
1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May; 220(4599): 868-71. 2. Anglaret X. [Global AIDS epidemic: from epidemiology to universal treatment]. Rev Med Interne. 2008 Dec; 29 Suppl 3:S269-73. doi: 10.1016/j.revmed.2008.10.002 [Article in French] 3. Arora DR, Gautam V, Gill PS, Mishra N. Recent advances in antiretroviral therapy in HIV infection. J Indian Med Assoc. 2010 Jan; 108(1): 29-34. 4. Katzman M, Sudol M, Pufnock JS, Zeto S, Skinner LM. Mapping target site selection for the non-specific nuclease activities of retroviral integrase. Virus Res. 2000; 66(1): 87-100. 5. Cook PR. A model for reverse transcription by a dimeric enzyme. Journal of General Virology. 1993;74(4): 691-7. doi:10.1099/0022-1317-74-4-691 6. Sakuragi J, Iwamoto A, Shioda T. Dissociation of genome dimerization from packaging functions and virion maturation of human immunodeficiency virus type 1. J Virol. 2002; 76(3): 959-67. doi:10.1128/JVI.76.3.959-967.2002 7. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988 Aug; 20(4): 309-21. 8. Wang RR, Gu Q, Wang YH, Zhang XM, Yang LM, Zhou J, et al. Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis. J Ethnopharmacol. 2008 May; 117(2): 249-56. doi:10.1016/j.jep.2008.01.037 9. Madani N, Hubicki AM, Perdigoto AL, Springer M, Sodroski J. Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry. J Virol. 2007; 81(2): 532-8. doi:10.1128/JVI.01079-06 10. Zabihollahi R, Sadat SM, Vahabpour R, Aghasadeghi MR, Memarnejadian A, Ghazanfari T, et al. Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virol. 2011; 55(1): 15-22. 11. Sadat SM, Zabihollahi R, Vahabpour R, Azadmanesh K, Javadi F, Siadat SD, et al. Designing and biological evaluation of single cycle replicable HIV-1 system as a potential vaccine strategy. Clinical Microbiology and Infection. 2010 Nov; 16(2): S334. 12. Rezaei A, Zabihollahi R, Salehi M, Moghim SH, Tamizifar H, Yazdanpanahi N, et al. Designing a non-virulent HIV-1 strain:Potential implications for vaccine and experimental research. Journal of Research in Medical Sciences. 2007; 12(5): 227-34. 13. Campbell EM, Perez O, Melar M, Hope TJ. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology. 2007; 360(2): 286-93. doi:10.1016/j.virol.2006.10.025 14. Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene WC. HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology. 2004 Oct; 328(1):36-44. doi:10.1016/j.virol.2004.07.015 15. Morgan JR, LeDoux JM, Snow RG, Tompkins RG, Yarmush ML. Retrovirus infection: effect of time and target cell number. J Virol. 1995 Nov; 69(11): 6994-7000. 16. Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol. 2004 Apr; 78(7): 3210-22. 17. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, et al. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology. 2005 Sep; 339(2): 213-25. 18. Ahmed N, Brahmbhatt KG, Sabde S, Mitra D, Singh IP, Bhutani KK. Synthesis and anti-HIV activity of alkylated quinoline 2,4-diols. Bioorg Med Chem. 2010 Apr; 18(8): 2872-9. doi:10.1016/j.bmc.2010.03.015 19. Nagasawa JY, Song J, Chen H, Kim HW, Blazel J, Ouk S, et al. 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors. Bioorg Med Chem Lett. 2011 Jan; 21(2): 760-3. doi:10.1016/j.bmcl.2010.11.108 20. Asaadi Dalaei S, Zabihollahi R, Sadat S M, Siadat SD, Amirmozafari N, Farhang Esfahani A, et al. [Inhibitory Effects of Novel 3-Hydroxy-4-Pyridinones with Iron Chelating Activity against Production of HIV Virions]. J Mazandaran Univ Med Sci. 2013; 22(97): 179-87. [Article in Persian] 21. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem. 2006 Mar; 49(5): 1506-8. 22. Hajimahdi Z, Zabihollahi R, Aghasadeghi M, Ashtiani SH, Zarghi A. Novel quinolone-3-carboxylic acid derivatives as anti-HIV-1 agents: design, synthesis, and biological activities. Medicinal Chemistry Research. 2016; 25(9): 1861-77. doi:10.1007/s00044-016-1631-x
|
